Diseases associated with helicobacter pylori

Medical Journal of Australia

Volumn 169, Issue 4, 1998, Pages 220-225

  Dev, Anouk T ^a,b   Lambert, John R ^a,c,d  

^a FRANKSTON HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d PPD Pharmaco Lockton House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; BISMUTH CITRATE; CLARITHROMYCIN; HELIDAC; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; UNCLASSIFIED DRUG; UREA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BREATH ANALYSIS; CARCINOGENESIS; CLINICAL FEATURE; DIARRHEA; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPEPSIA; ENDOSCOPE; ERADICATION THERAPY; GASTRITIS; GASTRODUODENAL ULCER; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NAUSEA; PATHOGENESIS; PATIENT COMPLIANCE; PSEUDOMEMBRANOUS COLITIS; REVIEW; SERODIAGNOSIS; SIDE EFFECT; STOMACH ADENOCARCINOMA; TASTE DISORDER;

EID: 0031683015     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1998.tb140228.x     Document Type: Review

References (30)

1. Warren JR, Marshall BJ. Unidentified curved bacilli in gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-1275.
2. Lambert JR, Lin SK, Aranda-Michel J. Helicobacter pylori. Scand J Gastroenterol 1995; 30: 33-46.
3. Lee A. The microbiology and epidemiology of Helicobacter pylori infection. Scand J Gastroenterol 1994; 29 Suppl 201: 2-6.
4. Veldhuyzen van Zanten SJO. Do socio-economic status, marital status and occupation influence the prevalence of Helicobacter pylori infection? Aliment Pharmacol Ther 1995; 9 Suppl 2: 41-44.
5. Lin SK, Lambert JR, Chow T. Comparison of Helicobacter pylori in three ethnic groups. Gastroenterology 1991; 100: A111.
6. Cullen DJE, Collins BJ, Christiansen KJ, et al. When is Helicobacter pylori infection acquired? Gut 1993; 34: 1681-1682.
7. Megraud F. Transmission of Helicobacter pylori: faecal-oral versus oral-oral route. Aliment Pharmacol Ther 1995; 9 Suppl 2: 85-91.
8. Tytgat GN. Endoscopic transmission of Helicobacter pylori. Aliment Pharmacol Ther 1995; 9 Suppl 2: 105-110.
9. Tee W, Lambert JR, Pergorer M, Dwyer B. Cytotoxin production by H. pylori more common in peptic ulcer disease. J Clin Microbiol 1995; 33: 1203-1205.
10. Figura N. Helicobacter pylori exotoxins and gastroduodenal diseases associated with cytotoxin strain infection. Aliment Pharmacol Ther 1996; 10 Suppl 1: 79-96.
11. Price AB. The Sydney system: histological diseases. J Gastroenterol Hepatol 1991; 6: 209-222.
12. Kuipers EJ, Uyterline AM, Pena AS, et al. Long term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-1528.
13. Niemalas S, Karttunen T, Kerola T, Karttunen R. Ten year follow-up study of lymphocytic gastritis: further evidence of Helicobacter pylori as a cause of lymphocytic gastritis and corpus gastritis. J Clin Pathol 1995; 48: 111-116.
14. Lin SK, Lambert JR. Helicobacter pylori in ulcerogenesis. Scand J Gastroenterol 1995; 95: 64-69.
15. Rauws EAJ, Tytgat GNJ. Helicobacter pylori in duodenal and gastric ulcer disease. Baillieres Clin Gastroenterol 1995; 9: 529-547.
16. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am 1993; 22:89-103.
17. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19 Suppl 10: 537-543.
18. Cammarota G, Tursi A, Montalto M, et al. Prevention and treatment of low-grade B-cell primary gastric lymphoma by anti-H. pylori therapy. J Clin Gastroenterol 1995; 21: 118-122.
19. Australian Gastroenterology Institute. Helicobacter pylori guidelines for health care providers. Sydney: Gastroenterological Society of Australia, 1995.
20. Digestive Health Initiative International Update Conference of Helicobacter pylori. Report. Presented at Digestive Disease Week, Washington DC May 1997. In press.
21. Malfertheiner P, Megraud F, O'Morain C, et al. Current European concepts in management of H. pylori infection. The Maastricht consensus report. Eur J Gastroenterol Hepatol 1997; 9: 1-3.
22. Lin SK, Lambert JR, Schembri M. A comparison of diagnostic tests to determine Helicobacter pylori infection. J Gastroenterol Hepatol 1992; 7: 203-209.
23. Sung JJU, Chung SCS, Ling YKW, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995; 332: 139-142.
24. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole and ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 719-726.
25. Hawkey CJ, Karrash JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-734.
26. Bolin TD, Hunt RH, Korman MG, et al. Helicobacter pylori and gastric metaplasia: evolving concepts. Med J Aust 1995; 163: 253-255.
27. Talley NJ. A critique in therapeutic trials in H. pylori positive functional dyspepsia. Gastroenterology 1994; 106: 1174-1183.
28. Van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: a review of world literature. Helicobacter 1996; 1: 6-19.
29. Forbes GM, Coombs GW, Collins BJ, et al. Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance. Aust N Z J Med 1998; 28: 13-17.
30. Axon ATR, Ireland A, Lancaster Smith MJ, Rooprams PD. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 81-87.